Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides.

Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides.

Despite more than 25 years of research, the molecular targets of quinoline-3-carboxamides have been elusive although these compounds are currently in Phase II and III development for treatment of autoimmune/inflammatory diseases in humans. Using photoaffinity cross-linking of a radioactively labelle...

Full description

Bibliographic Details
Main Authors: Per Björk, Anders Björk, Thomas Vogl, Martin Stenström, David Liberg, Anders Olsson, Johannes Roth, Fredrik Ivars, Tomas Leanderson
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2009-04-01
Series:PLoS Biology
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19402754/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19402754/?tool=EBI

Similar Items